EmergenciesER2NCT03633240
Emergency Room Visits and Older Patients (ER2)
An observational study of Emergencies and Length of Stay, run by Jewish General Hospital at 1 site in Canada.
Trial summary
Today's population is living longer than prior generations. Senior patients, defined as 65 years or older, are therefore increasing in number, and representing a larger number of hospitalized patients. Thus, assessing and addressing the needs of the growing number of older ER users is essential. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Emergencies, Length of Stay
- What is being tested?
- ER assessment
- How many people
- 356 participants
- Where
- 1 siteCanada
- Study dates
- 1 Sep 2017to 1 Jul 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Older adult
Study population: They will be separated in four main groups: 1. Those without any PRISMA-7 and ER2. 2. Those with PRISMA-7 and without ER2. 3. Those with ER2 and without PRISMA-7. 4. Those with PRISMA-7 and ER2. Each group of participants with PRISMA-7 and ER2 will be divided in two subgroups: those with all items completed and a score, and those with incomplete tools.
Who may be able to join
- Age ≥ 65 years.
- Unplanned ER visits.
Who cannot join
- Death within the 24 hours of first visiting ER.
- Palliative care due to ER visit.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Emergency Room Visits and Older Patients: Assessment of Jewish General Hospital Program Screening Frail Users
Today's population is living longer than prior generations. Senior patients, defined as 65 years or older, are therefore increasing in number, and representing a larger number of hospitalized patients. Thus, assessing and addressing the needs of the growing number of older ER users is essential. The overall objective of the study is to examine the feasibility and the epidemiology of two screening tools ("Programme de Recherche sur l'Intégration des Services pour le Maintien de l'Autonomie" (PRISMA-7) and Emergency Room Evaluation and recommendations (ER2)) used in the Emergency Room of Jewish General Hospital to screen older patients (i.e.; ≥65 years) at risk of adverse health events. A prospective observational cohort design will be used for the study's two phases; phase 1- assessment and phase 2- assessment as well as recommendations.
- Conditions
- Emergencies, Length of Stay
- Being tested
- ER assessment
- Medical subject headings
- Emergencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ER assessmentOther
To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:
The first step will be limited to its assessment component in order to learn how to use the tool.
The second step will be to follow the recommendations provided after the assessment.
Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days.
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of using both tools in the ER
Percentage of participants with complete filed tools (older patients with tools filed / (older patients visiting the ER) x 100) will be calculated.
Measured: 1 day
Prevalence of tools filed
Prevalence will be calculated for PRISMA-7, ER2 and pooled tools respectively.
Measured: 1 day
Secondary outcomes (3)
Feasibility of tools
Estimation of quality of filling using the percentage of items filled in for participants with an incomplete tool.
Measured: 1 day
Length of stay
The LHS will be calculated using the administrative registry of the JGH and will correspond to the delay in days between the first day of admission to ED and the last day of hospitalization in the acute ward(s).
Measured: 1 day
Acute medical events
Acute medical events occurring during the period of the ER visit and admission to the medical or surgery ward (acute organ failure, nosocomial infection, fall or death)
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2018
- Study start1 Sep 2017
- Primary completion1 Sep 2021
- Study completion1 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for EmergenciesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 356 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jewish General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olivier Beauchet, Jewish General Hospital
- Investigators
- Olivier Beauchet, Principal investigator, Jewish General Hospital - Lady Davis Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03633240
- Sponsor's protocol ID
- CODIM-16 315
- Acronym
- ER2
- Status last verified
- Jul 2024
- First submitted
- 9 Aug 2018
- Last updated
- 23 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Beauchet O, Afilalo M, Allali G, Lubov J, Galery K, Launay CP. "Emergency Room Evaluation and Recommendations" and Incident Hospital Admissions in Older People with Major Neurocognitive Disorders Visiting Emergency Department: Results of an Experimental Study. Dement Geriatr Cogn Disord. 2022;51(3):291-296. doi: 10.1159/000524533. Epub 2022 May 12.
PubMed 35551122
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Emergency Room Visits and Older Patients: Assessment of Jewish General Hospital Program Screening Frail Users
- ClinicalTrials.gov ID
- NCT03633240
- Acronym / sponsor ID
- ER2 / CODIM-16 315
- Conditions
- Emergencies, Length of Stay
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 356 participants (actual)
- Lead sponsor
- Jewish General HospitalUniversity, hospital or other
- Study start
- 1 Sep 2017 (actual)
- Primary completion
- 1 Sep 2021 (actual)
- Study completion
- 1 Jul 2024 (actual)
- First posted
- 16 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Today's population is living longer than prior generations. Senior patients, defined as 65 years or older, are therefore increasing in number, and representing a larger number of hospitalized patients. Thus, assessing and addressing the needs of the growing number of older ER users is essential. The overall objective of the study is to examine the feasibility and the epidemiology of two screening tools ("Programme de Recherche sur l'Intégration des Services pour le Maintien de l'Autonomie" (PRISMA-7) and Emergency Room Evaluation and recommendations (ER2)) used in the Emergency Room of Jewish General Hospital to screen older patients (i.e.; ≥65 years) at risk of adverse health events. A prospective observational cohort design will be used for the study's two phases; phase 1- assessment and phase 2- assessment as well as recommendations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Age groups
- Older adult
- Study population
- They will be separated in four main groups: 1. Those without any PRISMA-7 and ER2. 2. Those with PRISMA-7 and without ER2. 3. Those with ER2 and without PRISMA-7. 4. Those with PRISMA-7 and ER2. Each group of participants with PRISMA-7 and ER2 will be divided in two subgroups: those with all items completed and a score, and those with incomplete tools.
Key inclusion criteria (2 listed)
- Age ≥ 65 years.
- Unplanned ER visits.
Key exclusion criteria (2 listed)
- Death within the 24 hours of first visiting ER.
- Palliative care due to ER visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ER assessmentTo measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps: The first step will be limited to its assessment component in order to learn how to use the tool. The second step will be to follow the recommendations provided after the assessment. Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days. | Other | – |
Primary outcome
Feasibility of using both tools in the ER
Time frame: 1 day
Percentage of participants with complete filed tools (older patients with tools filed / (older patients visiting the ER) x 100) will be calculated.
Prevalence of tools filed
Time frame: 1 day
Prevalence will be calculated for PRISMA-7, ER2 and pooled tools respectively.
3 secondary outcomes
Feasibility of tools
Time frame: 1 day
Length of stay
Time frame: 1 day
Acute medical events
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2024.
- Derived from this study: PubMed 35551122Beauchet O, Afilalo M, Allali G, Lubov J, Galery K, Launay CP. "Emergency Room Evaluation and Recommendations" and Incident Hospital Admissions in Older People with Major Neurocognitive Disorders Visiting Emergency Department: Results of an Experimental Study. Dement Geriatr Cogn Disord. 2022;51(3):291-296. doi: 10.1159/000524533. Epub 2022 May 12.
- Individual participant dataSharing planned: No
Related trials for Emergencies
Not yet recruiting
Miniature In-line Respirator
Brain Death, Respiration, Artificial
Enrolling by invitation
Improving In-hospital and Post-discharge Patient Education for Mild Traumatic Brain Injury
Concussion, Mild, Traumatic Brain Injury
RecruitingObservational study
Clinical Management and Outcomes After Lung Scintigraphy for Suspected Pulmonary Embolism in the Emergency Department
Pulmonary Embolism (Diagnosis)
Recruiting
Sustained Cord Circulation at Emergency Cesarean Section
Asphyxia Neonatorum, Fetal Hypoxia
RecruitingObservational study
POS-ARI-ER Observational Study of Acute Respiratory Infections
Acute Respiratory Infection, Acute Respiratory Tract Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Olivier Beauchet principal investigator
Jewish General Hospital - Lady Davis Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Emergencies and Length of Stay, run by Jewish General Hospital at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of using both tools in the ER (time frame: 1 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03633240, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.